Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients.
Idan YelinKelly B FlettChristina MerakouPreeti MehrotraJason StamErik SnesrudMary HinkleEmil LeshoPatrick McGannAlexander J McAdamThomas J SandoraRoy KishonyGregory P PriebePublished in: Nature medicine (2019)
Probiotics are routinely administered to hospitalized patients for many potential indications1 but have been associated with adverse effects that may outweigh their potential benefits2-7. It is particularly alarming that probiotic strains can cause bacteremia8,9, yet direct evidence for an ancestral link between blood isolates and administered probiotics is lacking. Here we report a markedly higher risk of Lactobacillus bacteremia for intensive care unit (ICU) patients treated with probiotics compared to those not treated, and provide genomics data that support the idea of direct clonal transmission of probiotics to the bloodstream. Whole-genome-based phylogeny showed that Lactobacilli isolated from treated patients' blood were phylogenetically inseparable from Lactobacilli isolated from the associated probiotic product. Indeed, the minute genetic diversity among the blood isolates mostly mirrored pre-existing genetic heterogeneity found in the probiotic product. Some blood isolates also contained de novo mutations, including a non-synonymous SNP conferring antibiotic resistance in one patient. Our findings support that probiotic strains can directly cause bacteremia and adaptively evolve within ICU patients.
Keyphrases
- intensive care unit
- end stage renal disease
- genetic diversity
- newly diagnosed
- ejection fraction
- chronic kidney disease
- escherichia coli
- prognostic factors
- peritoneal dialysis
- mechanical ventilation
- genome wide
- patient reported outcomes
- copy number
- risk assessment
- machine learning
- deep learning
- big data
- electronic health record
- climate change
- patient reported
- multidrug resistant